About TERN-501 FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlight ...

Company Overview - Terns Pharmaceuticals, Inc. (TERN) is a clinical-stage biopharmaceutical company focusing on developing small molecule product candidates in oncology and obesity [4][11]. - The company has a promising pipeline that includes TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a GLP-1 receptor agonist for obesity [5][14]. Financial Performance - Terns has shown a year-to-date (YTD) stock price increase of 13.6%, outperforming the industry, which has declined by 7% [10][17]. - As of March 31, 2024, Terns reported cash, cash equivalents, and marketable securities totaling $240.7 million, which is expected to fund its operations into 2026 [7]. Pipeline Development - TERN-701 has demonstrated superior efficacy and safety compared to traditional tyrosine kinase inhibitors, with ongoing phase I trials showing promising results [5][12]. - The company is also conducting a phase I study (CARDINAL) for TERN-701 in CML, with interim data expected in the second half of 2024 [18]. - Terns plans to report top-line 28-day weight loss data for TERN-601 in the second half of 2024, capitalizing on the lucrative obesity market [21]. Regulatory Progress - In March 2024, TERN-701 received orphan drug designation from the FDA for the treatment of CML, which may enhance its market potential [19]. Competitive Landscape - TERN-701 is positioned as a differentiated treatment option compared to Novartis' Scemblix, offering more convenient dosing for CML patients [6][20]. - The company is also exploring the potential of GIPR antagonist combinations for obesity treatment, indicating a strategic focus on innovative therapies [16].

Shares of Terns Pharmaceuticals, Inc. (TERN) have gained 3.8% over the past four weeks to close the last trading session at $6.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.21 indicates a potential upside of 136.4%. The mean estimate comprises seven short-term price targets with a standard deviation of $5.92. While the lowest estimate of $5.50 indicates an 8.5% decline ...

The Company granted to Scott Harris, the Company's new Chief Development Officer, an option to purchase 475,000 shares of Terns common stock as of May 28, 2024, and to the other non-executive employee an option to purchase 36,000 shares of Terns common stock as of June 1, 2024. FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to a ...

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, June 5, ...

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, June 5, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39926 Terns Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 98-1448275 (State or other juri ...

Exhibit 99.1 Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR- ABL) in CML expected in 2H24 "We continue to execute our strategy and make important progress on our pipeline of potential best-in-class small molecule therapies as we prepare for key data readouts from our two lead programs," said Amy Burroughs, chief executive officer of Terns, "We look forward to re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39926 Terns Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-1448275 (State or other jurisdic ...

Exhibit 99.1 Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in second half of 2024 Cash, cash equivalents and marketable securities of $263 million, expected to provide runway into 2026 FOSTER CITY, Calif., Mar. 14, 2024 ...